The long-acting antiretroviral cabotegravir and rilpivirine combination has just received FDA,
EMA and Health Canada approval. This novel drug delivery approach is about to …

Key population perceptions and opinions about long-acting an... : Current Opinion in HIV and
AIDS Key population perceptions and opinions about long-acting antiretrovirals for prevention …

Introduction Approval of the first long‐acting injectable antiretroviral therapy (LAI ART)
medication heralded a new era of HIV treatment. However, the years since approval have …

Broadly neutralizing antibodies for treatment and prevention... : Current Opinion in HIV and
AIDS Broadly neutralizing antibodies for treatment and prevention of HIV-1 infection : Current …

Introduction: Mobility is common and an essential livelihood strategy in sub-Saharan Africa
(SSA). Mobile people suffer worse outcomes at every stage of the HIV care cascade …

Immunotherapeutic interventions to enhance natural HIV-specific CD8+ T cell responses,
such as vaccination or adoptive T cell transfer, have been a major focus of HIV cure efforts …

Long-acting (LA) anti-HIV regimens show promise for increasing dosing intervals and
consequently, improving the patients' quality of life. The first FDA-approved LA therapy is …

Although progress with newer cure strategies may be encouraging, challenges remain and it
is essential to achieve a high threshold of safety and effectiveness in the era of safe and …

Introduction HIV is a global disease that has seen significant improvements in care over the
past decades. Despite improvements, treatments for maintaining suppression are complex …

The first long-acting injectable drug regimen for HIV antiretroviral therapy (ART) has
received regulatory approval in the United States (USA) and Canada [1, 2]. A monthly …